Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.400 GeneticVariation disease BEFREE Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. 31548343 2020
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.400 GeneticVariation disease BEFREE MET c-Cbl binding site mutations constitute about 2 % of MET exon 14 alterations in lung cancer. 31809977 2020
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.400 Biomarker disease BEFREE Dual inhibition of EGFR and MET by Echinatin retards cell growth and induces apoptosis of lung cancer cells sensitive or resistant to gefitinib. 31698509 2020
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.400 Biomarker disease BEFREE Amplification of the de novo MET gene was identified in 47 patients with lung cancer. 30554986 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.400 GeneticVariation disease BEFREE The presence of MET exon 14 mutations in minor histological types of lung cancers urge to extend screening scope of this mutation in lung cancer and treatment response evaluation in clinical trials. 31369639 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.400 Biomarker disease BEFREE KRAS mutations may act as a resistance mechanism to MET inhibition in MET dependent lung cancer. 31200822 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.400 AlteredExpression disease BEFREE A significant positive correlation between MET and PD-L1 expression in lung cancer was determined in an analysis based on The Cancer Genome Atlas (TCGA) and in an immunohistochemistry study. 31480591 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.400 AlteredExpression disease BEFREE Sarcomatoid transformation is a type of lung cancer histologic evolution with a poor prognosis and a high proportion of cases with aberrant MET activation and PD-L1 expression. 31561203 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.400 GeneticVariation disease BEFREE Here, we report the dysregulation of mutant MET originally found in a lung cancer patient with Val370 to Asp370 (V370D) replacement located in the extracellular SEMA domain. 31342590 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.400 Biomarker disease BEFREE [Corrigendum] AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis. 30542697 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.400 Biomarker disease BEFREE Therefore EGFR and MET may be attractive targets for lung cancer therapy. 31323446 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.400 Biomarker disease BEFREE We found a panel of benzisoselenazolones (BISAs) obtained by introducing isothiourea, tetramethylthiourea and heterocyclic groups into the C-ring of Ebselen, including <b>7a</b>, <b>7b</b>, <b>8a</b>, <b>8b</b> and <b>12c</b> (with IC<sub>50</sub> values of less than 20 μM in MET gene amplified lung cancer cell line EBC-1), exhibited more potent antitumour activity than Ebselen by cell growth assay combined with in vitro biochemical assays. 31137515 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.400 Biomarker disease BEFREE A 1-MET increase and categories of moderate and high CRF were associated with 10%, 47% and 65% reduction in lung cancer incidence (p=0.002), and 13%, 58% and 76% reduction in cancer mortality (p=0.002), respectively. 30803499 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.400 Biomarker disease BEFREE It was revealed that LINC00887 interacts with several microRNAs (miRs), which regulates downstream genes such as fibronectin 1, MET proto‑oncogene, receptor tyrosine kinase and mothers against decapentaplegic homolog 4, which are associated with the spread of lung cancer. 31322230 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.400 GeneticVariation disease BEFREE MNNG HOS Transforming gene (MET) amplification and MET exon 14 (METex14) alterations in lung cancers affect sensitivity to MET proto-oncogene, receptor tyrosine kinase (MET [also known by the alias hepatocyte growth factor receptor]) inhibitors. 31228623 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.400 Biomarker disease BEFREE MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. 31227004 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.400 Biomarker disease BEFREE We have already demonstrated an implication of MET and RON genes in brain metastases from lung cancer. 30813513 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.400 Biomarker disease BEFREE This study provides preclinical evidences that combination therapy of CsA and crizotinib is a promising approach for targeted treatment of MET-amplified lung cancer patients. 30879923 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.400 Biomarker disease BEFREE Erratum: Stella, G.M. et al. Brain Metastases from Lung Cancer: Is MET an Actionable Target? <i>Cancers</i> 2019, <i>11</i>, 271. 31083323 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.400 AlteredExpression disease BEFREE The cytotoxicity assay results revealed that c‑MET‑CAR‑NK cells exhibited more specific cytotoxicity for HepG2 cells with high c‑MET expression compared with the lung cancer cell line H1299, which has low levels of c‑MET expression. 31524233 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.400 Biomarker disease BEFREE Among former smokers, 1-MET increase and categories of moderate and high cardiorespiratory fitness were associated with 13% (p=0.016), 51%, and 77% (p-trend=0.015) reductions in lung cancer incidence, respectively. 31564605 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.400 Biomarker disease BEFREE Further prospective studies with more participants for better understanding of mechanism and effect for HGF and c-MET inhibitors in lung cancer will help us to identify of these biomarkers role for guiding us to sellect individualized itargeted therapies. 31104010 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.400 Biomarker disease BEFREE <i>KRAS</i> mutation is a recurrent mechanism of primary and secondary resistance to MET TKIs in <i>MET</i>ex14 lung cancers. 30352902 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.400 Biomarker disease BEFREE Taken together, GM-CSF combined with MET PTX exerted a synergistic anti-tumor effect against lung cancer in a mouse model through an antiangiogenic activity and inducing dendritic cells maturation without exerting pronounced adverse effects. 29435154 2018
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.400 Biomarker disease BEFREE Silencing of Long Noncoding RNA <i>MIR22HG</i> Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer. 29669758 2018